The aims of this study were to investigate the clinical effects of I-125 implantation combined with radiofrequency ablation in treating bone metastases (BM) and analyze its clinical application so as to provide better treatment protocols for the treatment of BM. A total of 63 BM patients were randomly divided into the I-125 implantation group (CON, treated with I-125 seeds alone, 33 patients) and the combination group (I-125-MA, 30 patients) to compare the clinical efficacy and adverse effects. After treatment, the clinical efficacy of Group I-125-MA was significantly better than Group CON, and the quality of life was improved significantly (P < 0.05). I-125-MA has relatively better clinical efficacy in treating BM, which can not only significantly improve patients' life quality but also cause no serious adverse reaction. The therapy of I-125 implantation combined with radiofrequency ablation provides a new idea for treating bone metastases. Compare Group I-125 -MA and Group CON, remission rates of bone pain were 76.7% vs 42.4% (P < 0.05); movement ability: 73.3% vs 39.4% (P < 0.05); quality of life: improvement rates: 70% vs 42.4% (P < 0.05), the median initial time of relieve pain: 3.5 days vs 7.6 days (P < 0.05).